exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275221 RNA Name: hsa-miR-124-3p RNA Type: miRNA Chromosome: chr8 Starnd: + Coordinate: Start Site(bp): 64379210 End Site(bp): 64379231 External Links: hsa-miR-124-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CDH1 chr16 68737292 68835541 + MDK chr11 46380756 46383837 + TRAPPC10 chr21 44012309 44106552 + COL12A1 chr6 75084326 75206053 - RANBP10 chr16 67723070 67806652 - TSEN54 chr17 75516060 75524735 + ZCCHC24 chr10 79382325 79445624 - ASF1B chr19 14119512 14136613 - RPS10-NUDT3 chr6 34284887 34426071 - JAG1 chr20 10637684 10673999 - RPS6KA3 chrX 20149911 20267519 - CTDSP1 chr2 218398256 218405941 + NUDT3 chr6 34279679 34392669 - FAM102A chr9 127940582 127980989 - MMS22L chr6 97142161 97283217 - EPHB4 chr7 100802565 100827523 - ANGPTL2 chr9 127087348 127122635 - BLOC1S5-TXNDC5 chr6 7881522 8064364 - PAPSS2 chr10 87659613 87747705 + C20orf27 chr20 3753508 3768387 - MOB4 chr2 197515571 197553699 + SCAMP2 chr15 74843730 74873365 - CDKN2A chr9 21967753 21995301 - G3BP2 chr4 75642782 75724525 - ZSCAN22 chr19 58326994 58342332 + ANKRD52 chr12 56237807 56258384 - NFAT5 chr16 69565094 69704666 + CREB3L2 chr7 137874979 138002086 - CLASP1 chr2 121337776 121649587 - MLLT1 chr19 6210381 6279975 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001186 chr21 35475133 35475818 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008040.1 chr3 169939353 169966734 - AC069281.2 chr7 100572232 100578700 - AC084082.1 chr8 66112667 66126632 + FGD5-AS1 chr3 14920347 14948424 - KCNQ1OT1 chr11 2608328 2699994 - LINC00240 chr6 26956932 27059749 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + TMEM147-AS1 chr19 35540738 35546029 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.